A detailed history of Broderick Brian C transactions in Abb Vie Inc. stock. As of the latest transaction made, Broderick Brian C holds 13,103 shares of ABBV stock, worth $2.3 Million. This represents 0.55% of its overall portfolio holdings.

Number of Shares
13,103
Previous 13,123 0.15%
Holding current value
$2.3 Million
Previous $2.25 Million 14.98%
% of portfolio
0.55%
Previous 0.5%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 06, 2024

SELL
$163.84 - $199.33 $3,276 - $3,986
-20 Reduced 0.15%
13,103 $2.59 Million
Q2 2024

Aug 12, 2024

BUY
$154.79 - $180.76 $79,097 - $92,368
511 Added 4.05%
13,123 $2.25 Million
Q1 2024

May 03, 2024

BUY
$159.82 - $182.1 $267,378 - $304,653
1,673 Added 15.29%
12,612 $2.3 Million
Q4 2023

Feb 13, 2024

SELL
$137.6 - $154.97 $173,100 - $194,952
-1,258 Reduced 10.31%
10,939 $1.7 Million
Q3 2023

Nov 14, 2023

SELL
$133.59 - $154.65 $9,351 - $10,825
-70 Reduced 0.57%
12,197 $1.82 Million
Q1 2023

May 10, 2023

SELL
$144.61 - $166.54 $10,122 - $11,657
-70 Reduced 0.57%
12,267 $1.95 Million
Q4 2022

Feb 09, 2023

SELL
$138.31 - $165.87 $93,359 - $111,962
-675 Reduced 5.19%
12,337 $2 Million
Q3 2022

Nov 08, 2022

SELL
$134.21 - $153.93 $30,197 - $34,634
-225 Reduced 1.7%
13,012 $1.75 Million
Q2 2022

Jul 19, 2022

SELL
$137.62 - $174.96 $285,561 - $363,042
-2,075 Reduced 13.55%
13,237 $2.03 Million
Q1 2022

May 17, 2022

SELL
$131.98 - $163.75 $77,868 - $96,612
-590 Reduced 3.71%
15,312 $2.48 Million
Q4 2021

Feb 08, 2022

SELL
$107.43 - $135.93 $1,074 - $1,359
-10 Reduced 0.06%
15,902 $2.15 Million
Q3 2021

Nov 10, 2021

SELL
$106.4 - $120.78 $6,916 - $7,850
-65 Reduced 0.41%
15,912 $1.72 Million
Q2 2021

Aug 09, 2021

SELL
$105.21 - $117.21 $12,625 - $14,065
-120 Reduced 0.75%
15,977 $1.8 Million
Q1 2021

May 17, 2021

SELL
$102.3 - $112.62 $1,534 - $1,689
-15 Reduced 0.09%
16,097 $1.74 Million
Q3 2020

Oct 28, 2020

BUY
$85.91 - $100.83 $107,988 - $126,743
1,257 Added 8.46%
16,112 $1.41 Million
Q2 2020

Jul 28, 2020

SELL
$73.37 - $98.18 $48,424 - $64,798
-660 Reduced 4.25%
14,855 $1.46 Million
Q1 2020

May 07, 2020

SELL
$64.5 - $97.79 $645 - $977
-10 Reduced 0.06%
15,515 $1.18 Million
Q4 2019

Jan 15, 2020

SELL
$72.13 - $90.25 $66,720 - $83,481
-925 Reduced 5.62%
15,525 $1.38 Million
Q3 2019

Nov 04, 2019

SELL
$62.98 - $75.72 $119,662 - $143,868
-1,900 Reduced 10.35%
16,450 $1.25 Million
Q2 2019

Jul 24, 2019

SELL
$65.7 - $83.98 $47,632 - $60,885
-725 Reduced 3.8%
18,350 $1.33 Million
Q1 2019

Apr 29, 2019

SELL
$77.14 - $90.79 $34,327 - $40,401
-445 Reduced 2.28%
19,075 $1.54 Million
Q4 2018

Jan 24, 2019

SELL
$77.85 - $96.01 $72,789 - $89,769
-935 Reduced 4.57%
19,520 $1.8 Million
Q3 2018

Oct 15, 2018

SELL
$88.91 - $98.84 $13,336 - $14,826
-150 Reduced 0.73%
20,455 $1.93 Million
Q2 2018

Jul 30, 2018

SELL
$89.78 - $106.23 $67,335 - $79,672
-750 Reduced 3.51%
20,605 $1.91 Million
Q1 2018

Apr 24, 2018

SELL
$92.01 - $123.21 $75,448 - $101,032
-820 Reduced 3.7%
21,355 $2.02 Million
Q4 2017

Feb 02, 2018

SELL
$89.56 - $98.21 $421,827 - $462,569
-4,710 Reduced 17.52%
22,175 $2.14 Million
Q3 2017

Oct 26, 2017

BUY
$69.85 - $89.22 $1.88 Million - $2.4 Million
26,885
26,885 $2.39 Million

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $310B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Broderick Brian C Portfolio

Follow Broderick Brian C and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Broderick Brian C, based on Form 13F filings with the SEC.

News

Stay updated on Broderick Brian C with notifications on news.